Print
Print
Advertisement
Melissa BadamoAcute Myeloid Leukemia | June 3, 2024
Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline.
Read More
Leah SherwoodMyelofibrosis | May 22, 2024
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Leah LawrenceTransplantation & Cellular Therapy | May 22, 2024
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
Patrick DalyAcute Myeloid Leukemia | May 21, 2024
The patient, a 63-year-old male, was diagnosed with HIV-1 infection 31 years before undergoing transplantation.
Patrick DalyPrint | May 21, 2024
A meta-analysis of 24 studies observed a decrease in pediatric cancer treatment abandonment after the intervention.
Advertisement
Melissa BadamoAcute Myeloid Leukemia | May 21, 2024
Oral tamibarotene is currently being evaluated in combination with azacitidine and venetoclax in the SELECT-AML-1 trial.
Patrick DalyMyeloma | May 21, 2024
Cilta-cel is now indicated for adult patients who have received at least one prior line of therapy.
Patrick DalyPrint | May 15, 2024
Monotherapy with tagraxofusp induced complete remissions in patients with blastic plasmacytoid dendritic cell neoplasm.
Melissa BadamoPrint | May 15, 2024
Tagraxofusp is the first drug for BPDCN, and the first CD123-targeting drug in oncology, to receive FDA approval.
Melissa BadamoPrint | April 30, 2024
Palliative care facilitates communication and helps with symptom management, the researchers noted.
Patrick DalyMyeloma | April 19, 2024
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Melissa BadamoPrint | April 16, 2024
Dr. Vose discusses how she became a hematologist, how she nurtures her artistic side outside of work, and more.
Melissa BadamoPrint | May 21, 2024
Dr. Cavalli was honored for his accomplishments in the fields of leukemia, lymphoma, and breast cancer.
Melissa BadamoPrint | May 21, 2024
Dr. Witte’s recent research focuses on finding immunological targets for both antibody and cell-mediated therapy.
Leah SherwoodMyeloma | May 21, 2024
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
Melissa BadamoPrint | May 21, 2024
Dr. Shah’s areas of expertise include immunology and immunotherapy, rare tumors, CAR T-cell therapies, and transplantation.
Patrick DalyMyeloma | May 21, 2024
The expansion of the indication was supported by positive data from the KarMMa-3 study.
Melissa BadamoTransplantation & Cellular Therapy | May 21, 2024
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
Kami Maddocks, MDMantle Cell Lymphoma | April 3, 2024
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
Advertisement
Advertisement
Editorial Board